MX2018003100A - Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby. - Google Patents

Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby.

Info

Publication number
MX2018003100A
MX2018003100A MX2018003100A MX2018003100A MX2018003100A MX 2018003100 A MX2018003100 A MX 2018003100A MX 2018003100 A MX2018003100 A MX 2018003100A MX 2018003100 A MX2018003100 A MX 2018003100A MX 2018003100 A MX2018003100 A MX 2018003100A
Authority
MX
Mexico
Prior art keywords
pulmonary surfactant
lysin
restore
antibacterial activity
antibiotic
Prior art date
Application number
MX2018003100A
Other languages
Spanish (es)
Inventor
Schuch Raymond
Wittekind Michael
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2018003100A publication Critical patent/MX2018003100A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.
MX2018003100A 2015-09-17 2016-09-16 Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby. MX2018003100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220212P 2015-09-17 2015-09-17
US201562247619P 2015-10-28 2015-10-28
PCT/US2016/052348 WO2017049242A2 (en) 2015-09-17 2016-09-16 Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby

Publications (1)

Publication Number Publication Date
MX2018003100A true MX2018003100A (en) 2019-04-15

Family

ID=57121513

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018003100A MX2018003100A (en) 2015-09-17 2016-09-16 Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby.
MX2018003101A MX2018003101A (en) 2015-09-17 2016-09-16 Lysin polypeptides active against gram-negative bacteria.
MX2022006525A MX2022006525A (en) 2015-09-17 2018-03-13 Lysin polypeptides active against gram-negative bacteria.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2018003101A MX2018003101A (en) 2015-09-17 2016-09-16 Lysin polypeptides active against gram-negative bacteria.
MX2022006525A MX2022006525A (en) 2015-09-17 2018-03-13 Lysin polypeptides active against gram-negative bacteria.

Country Status (15)

Country Link
US (5) US10744189B2 (en)
EP (4) EP3349780B1 (en)
JP (3) JP7029805B2 (en)
KR (2) KR20180052754A (en)
CN (3) CN116077630A (en)
AU (3) AU2016324298B2 (en)
BR (2) BR112018005318A2 (en)
CA (2) CA2998484A1 (en)
ES (1) ES2934714T3 (en)
HK (1) HK1256628A1 (en)
IL (2) IL258122B (en)
MX (3) MX2018003100A (en)
RU (2) RU2724545C2 (en)
WO (2) WO2017049233A2 (en)
ZA (2) ZA201801316B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872911C (en) * 2012-05-09 2023-10-03 Contrafect Corporation Biofilm prevention, disruption and treatment with bacteriophage lysin
AU2015279705B2 (en) * 2014-06-26 2021-04-01 The Rockefeller University Acinetobacter lysins
CN104805066B (en) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 A kind of staphylolytic enzyme and its application
BR112018005318A2 (en) 2015-09-17 2018-12-11 Contrafect Corporation ? lysine polypeptides active against gram-negative bacteria?
EP3723789A4 (en) * 2017-12-12 2021-12-01 Contrafect Corporation Identification of lysins and derivatives thereof with bacterial activity against pseudomonas aeruginosa
US20210062137A1 (en) 2017-12-22 2021-03-04 The Rockefeller University Recombinant pseudomonas aeruginosa lysins
WO2019133804A1 (en) 2017-12-28 2019-07-04 Consegna Pharma Inc. Long acting opioid antagonists
AU2019245333A1 (en) * 2018-03-29 2020-10-29 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
MX2020010075A (en) * 2018-03-29 2021-01-08 Contrafect Corp Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof.
US10988520B2 (en) * 2018-03-29 2021-04-27 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
EP3813796A4 (en) * 2018-05-23 2022-06-22 The Rockefeller University Recombinant lysins
CA3104650A1 (en) * 2018-06-22 2019-12-26 Contrafect Corporation Lysins and derivatives thereof resensitize staphylococcus aureus and gram-positive bacteria to antibiotics
CN110664881A (en) * 2018-07-03 2020-01-10 上海海洋大学 Medicine for resisting aquatic pathogenic Citrobacter freundii and preparation method thereof
KR20210049023A (en) * 2018-08-23 2021-05-04 콘트라펙트 코포레이션 Lysine-antimicrobial peptide (AMP) polypeptide construct, lysine, isolated polynucleotide encoding the same, and uses thereof
US20220024992A1 (en) * 2018-11-02 2022-01-27 The Rockefeller University Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
JP2022525914A (en) * 2019-03-22 2022-05-20 コントラフェクト コーポレイション How to treat infective endocarditis
JP2022526978A (en) * 2019-04-05 2022-05-27 コントラフェクト コーポレイション Cytolysin and its derivatives that have bactericidal activity against Pseudomonas aeruginosa in the presence of human serum
US20220275061A1 (en) * 2019-07-12 2022-09-01 Contrafect Corporation Therapeutic protein formulations comprising antibodies and uses thereof
CN110684760A (en) * 2019-09-27 2020-01-14 吉林大学 Gene engineering lyase for killing staphylococcus and preparation method and application thereof
US20230138922A1 (en) 2020-03-11 2023-05-04 Telum Therapeutics S.L. New recombinant lysin and its use in the treatment of gram-negative bacterial infections
WO2021207679A1 (en) * 2020-04-10 2021-10-14 Liberty Biosecurity, Llc Polypeptide compositions and uses thereof
US20210324359A1 (en) * 2020-04-17 2021-10-21 Contrafect Corporation Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis
KR102228999B1 (en) * 2020-08-27 2021-03-18 주식회사 라이센텍 Polypeptide Variants and Antibiotics against Gram-Negative Bacteria Comprising the Same
WO2021235876A1 (en) * 2020-05-22 2021-11-25 주식회사 라이센텍 Novel polypeptide, fusion polypeptide, and antibiotic against gram-negative bacteria comprising same
KR102224897B1 (en) * 2020-05-22 2021-03-08 주식회사 라이센텍 Novel Polypeptide and Antibiotics against Gram-Negative Bacteria Comprising the Polypeptide
KR102419028B1 (en) * 2021-01-06 2022-07-08 주식회사 리신바이오 A novel recombinant endolysin derived from bacteriophage and use thereof
US11452757B2 (en) * 2021-02-25 2022-09-27 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023018199A1 (en) * 2021-08-09 2023-02-16 주식회사 레고켐바이오사이언스 Novel antibiotic and use thereof
WO2023034646A2 (en) * 2021-09-03 2023-03-09 Aanika Biosciences, Inc. Lysecd7 variants and methods of using the same
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
WO2023139605A1 (en) * 2022-01-20 2023-07-27 Techinvention Lifecare Pvt. Ltd. Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1536749A2 (en) 2002-07-08 2005-06-08 Joe S. Wilkins, Jr. Antibacterial formulations
US7572602B1 (en) * 2004-12-03 2009-08-11 The United States Of America As Represented By The Secretary Of Agriculture Nucleic acid encoding endolysin fusion protein
CN101094427B (en) 2006-06-23 2010-05-12 华为技术有限公司 System and method for collecting signaling message from whole network
JP5401457B2 (en) * 2007-07-26 2014-01-29 ルバンス セラピュティックス インク． Antibacterial peptide, composition and method of use thereof
KR20170024129A (en) * 2009-06-26 2017-03-06 카톨리에케 유니버시테이트 루벤 Antimicrobial agents
JP5847081B2 (en) 2009-08-24 2016-01-20 カトリック ユニバーシテイト ルーベン ケイ．ユー． ルーベン アール アンド ディー Endlysin OBPgpLYS
CN102021161A (en) 2009-09-22 2011-04-20 昆山博青生物科技有限公司 Preparation method for bacteriophage lyase of streptococcus pneumonia
EP3789031B1 (en) * 2010-09-17 2023-08-02 Technophage, Investigação e Desenvolvimento em Biotecnologia, SA Antibacterial phage, phage peptides and methods of use thereof
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
KR101859996B1 (en) * 2011-02-22 2018-05-21 디아이씨 가부시끼가이샤 Aqueous urethane resin composition, film obtained by using same, and optical film
CN107189997A (en) 2011-04-21 2017-09-22 洛克菲勒大学 The streptococcus bacteriophage lysin for detecting and treating for gram-positive bacteria
WO2012146738A1 (en) 2011-04-27 2012-11-01 Lysando Holding Ag New antimicrobial agents
WO2013044055A2 (en) 2011-09-23 2013-03-28 Quantum Engineered Products, Inc. Low profile jack
EP2849782B1 (en) * 2012-05-09 2020-03-18 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
EP2679677A1 (en) 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US9139626B2 (en) 2012-09-13 2015-09-22 The Mitre Corporation Mitrecin A polypeptide with antimicrobial activity
WO2014120074A2 (en) 2013-01-29 2014-08-07 Wideco Sweden Ab System for monitoring pipeline leakage, pipeline element provided with the system, and method for mounting the monitoring system onto a pipeline
WO2014124047A1 (en) 2013-02-06 2014-08-14 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
WO2015070911A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
BR112018005318A2 (en) * 2015-09-17 2018-12-11 Contrafect Corporation ? lysine polypeptides active against gram-negative bacteria?

Also Published As

Publication number Publication date
ZA201801315B (en) 2018-11-28
MX2022006525A (en) 2022-07-11
HK1256628A1 (en) 2019-09-27
JP7029805B2 (en) 2022-03-04
MX2018003101A (en) 2018-12-17
WO2017049233A3 (en) 2017-06-01
RU2018107245A (en) 2019-10-18
IL258123A (en) 2018-05-31
US10744189B2 (en) 2020-08-18
RU2724545C2 (en) 2020-06-23
RU2018107249A3 (en) 2020-01-10
AU2016324307B2 (en) 2021-10-21
EP3349780B1 (en) 2022-11-09
US20190070269A1 (en) 2019-03-07
IL258122B (en) 2020-08-31
JP2018534247A (en) 2018-11-22
JP2018527378A (en) 2018-09-20
AU2016324307A1 (en) 2018-03-22
IL258122A (en) 2018-05-31
BR112018005316A2 (en) 2018-12-11
AU2016324298A1 (en) 2018-03-22
AU2022252850A1 (en) 2022-11-17
EP3349781A2 (en) 2018-07-25
CN108135971A (en) 2018-06-08
EP4151228A2 (en) 2023-03-22
AU2016324298B2 (en) 2022-09-01
CA2998484A1 (en) 2017-03-23
US11413334B2 (en) 2022-08-16
CA2998507A1 (en) 2017-03-23
ZA201801316B (en) 2018-11-28
EP4151228A3 (en) 2023-06-14
IL258123B (en) 2021-03-25
US20200376096A1 (en) 2020-12-03
EP4115897A1 (en) 2023-01-11
EP3349780A2 (en) 2018-07-25
KR20180064417A (en) 2018-06-14
WO2017049242A3 (en) 2017-06-01
WO2017049233A2 (en) 2017-03-23
US20230050560A1 (en) 2023-02-16
BR112018005318A2 (en) 2018-12-11
ES2934714T3 (en) 2023-02-24
RU2728682C2 (en) 2020-07-31
JP2022065075A (en) 2022-04-26
US11357833B2 (en) 2022-06-14
CN108348574B (en) 2022-11-01
RU2018107245A3 (en) 2019-10-18
CN116077630A (en) 2023-05-09
KR20180052754A (en) 2018-05-18
WO2017049242A2 (en) 2017-03-23
US20220362352A1 (en) 2022-11-17
RU2018107249A (en) 2019-10-17
CN108348574A (en) 2018-07-31
US20190290672A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
MX2018003100A (en) Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby.
MX2020013776A (en) Treatment compositions providing an antimicrobial benefit.
BR112018069220A2 (en) use of polypeptide that has dnase activity for tissue treatment
MX2019013070A (en) Improved cleansing compositions.
MX359039B (en) Low ph composition comprising specific preservative systems.
MX2018005829A (en) Compositions for treating the hair.
MY194893A (en) Muscle atrophy inhibitor containing quercetin glycoside
MX2017007829A (en) An antimicrobial composition.
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
MX2022014634A (en) Methods for lymphatic delivery of active agents.
EP3727195A4 (en) Devices, treatments and methods to restore tissue elastic recoil
PH12017500615B1 (en) Ophthalmic composition comprising cyclosporine and trehalose
MX2018005796A (en) Reduction of stinging sensation on skin.
MX2020006596A (en) Hydroxyisoxazolines and derivatives thereof.
MX2018013184A (en) Compositions of saponins and plant extracts.
NZ738197A (en) Antihypertensive agent
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
MX2016015569A (en) Methods and compositions for immunomodulation.
PH12016502001B1 (en) Novel bacteriophage and composition comprising same
MX2018005028A (en) Skin care composition and method thereof.
MX2018000092A (en) New bicyclic lipolantipeptide, preparation and use as antimicrobial agent.
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
MX2018007468A (en) Collagen 7 compositions and methods of using the same.
ZA202000884B (en) Compositions for treating skin and mucous membrane infections
MX2016011572A (en) Organic acid antimicrobial compositions.